The subject has received bevacizumab for their disease unless in the context of primary therapy for newly diagnosed glioma Patients with newly diagnosed RMS of any subtype, except adult-type pleomorphic, based upon institutional histopathologic classification, are eligible to enroll on the study based upon stage, group, and age, as below Enrollment on ANBLB or APECB is required for all newly diagnosed patients Group C: patients < months (< days) of age with newly diagnosed INRG stage Ms neuroblastoma/ganglioneuroblastoma Newly diagnosed patients with histologically proven ALCL (International Classification of Diseases for Oncology [ICD-] code: /) Subject with histologically or cytologically confirmed extensive-stage disease SCLC which is newly diagnosed and chemotherapy naive Patients with CNS GCTs who are newly diagnosed are excluded from the study Newly-diagnosed brain cancer with histopathological diagnosis of GBM; Newly diagnosed acute myeloid leukemia in older patients (>= years) not candidates for intensive induction chemotherapy (Cohort ) Histologically confirmed newly diagnosed stage I-II HER/neu positive breast cancer History of previously treated ipsilateral or contralateral breast carcinoma is not an exclusion criteria if the investigator is certain newly diagnosed carcinoma is new unifocal primary tumor. Newly diagnosed mature B-lineage (CD positive) Leukemia/Lymphoma Be newly diagnosed and previously untreated Prior WBRT for newly diagnosed brain metastases Treatment naive for his or her newly diagnosed malignancy for enrollment to groups or newly diagnosed AML unsuitable for intensive chemotherapy For the Phase II part of the study, newly diagnosed OR refractory/metastatic anaplastic thyroid cancer confirmed by histology, incurable by surgery, radiotherapy or chemoradiotherapy alone or in combination Newly diagnosed, previously untreated participants with rhabdomyosarcoma (RMS) Patients with biopsy proven newly diagnosed rhabdomyosarcoma Have newly diagnosed localized or locally advanced (TN-M or T-NanyM), potentially resectable disease without any prior systemic chemotherapy Group : Must have newly diagnosed, pathologically confirmed cHL at Stages IA, IB and IIA without bulky disease. Group : Must have newly diagnosed, pathologically confirmed cHL at Stages IIEB, IIIEA,IIIEB, IIIB, IVA and IVB Elderly (> year old) patients with newly diagnosed AML not eligible for intensive chemotherapy Newly diagnosed patients who are ineligible or declined to receive intensive chemotherapy after discussion of risks and benefits of that approach or patients with primary refractory/relapsed AML Newly diagnosed brain cancer or tumor called glioblastoma or GBM Newly-diagnosed brain cancer or tumor called glioblastoma or GBM Must have recurrent disease confirmed by MRI (Group ) or completed SoC therapy such as surgery with adjuvant radiochemotherapy with or without maintenance temozolomide according to local standards for newly diagnosed disease (Group ) Patients with newly diagnosed, uncontrolled and or untreated cancer; related central nervous system diseases are excluded. Newly diagnosed androgen-sensitive metastatic disease; or Newly diagnosed, treatment naive, HNSCC suitable for surgical resection with planned radiotherapy and/or chemotherapy after surgery Newly diagnosed histologically proven locoregional OCSCC (T-stage -) without evidence of distant metastases; OCSCC includes the subsites of oral tongue, floor of mouth, gingiva, retromolar trigone, and buccal mucosa Newly diagnosed, biopsy proven cancer of the endometrium, prostate or breast Diagnosed with SMM within the last years Histopathologically proven newly-diagnosed primary glioblastoma with complete or partial surgical resection; biopsy not acceptable Newly diagnosed de novo AML; or Newly diagnosed (non-M) AML patients No diagnosed arrhythmias PHASE II DOSE EXPANSION IN NEWLY DIAGNOSED GBM: Is currently participating or has participated in any other newly diagnosed therapeutic trial before or after chemoradiation PHASE II DOSE EXPANSION IN NEWLY DIAGNOSED GBM: Has known gliomatous meningitis, extracranial disease, or multifocal disease Documented evidence of newly diagnosed, symptomatic MM, by IMWG criteria within five years of enrollment Newly diagnosed or relapsed participants are eligible to participate; this protocol is intended to enroll both previously treated and untreated patients Patients must have histologically confirmed newly diagnosed or previously untreated (patients may be under no treatment wait and watch or have received two cycles of chemotherapy or localized radiation therapy before going on this study) non-Hodgkins lymphoma or CLL Newly diagnosed, histologically confirmed breast cancer Patients with newly diagnosed AT/RT Patients with newly diagnosed AT/RT and synchronous extra-CNS MRT Patient has newly diagnosed disease with no prior therapy Currently receiving or scheduled to receive any other therapies intended to treat the newly diagnosed glioma prior to the MLA and the first post-MLA blood collection for correlative studies Any prior treatment for the current, newly diagnosed breast cancer Patient must have newly diagnosed, histologically confirmed GBM Patients with newly diagnosed stage I and II nasal NK cell lymphoma Four or more newly-diagnosed lesions The patient has newly-diagnosed, biopsy proven squamous cell carcinoma of stage I-IV (T-, N-b) of the oropharynx In the phase II portion, patients must be newly diagnosed or treatment naive, or have been off adjuvant imatinib therapy for at least months; patients with newly diagnosed GIST and who had been on imatinib for up to weeks prior to signing the consent are allowed to enroll in order to expedite accrual Newly diagnosed MCL: Confirmed diagnosis of MCL with CD and cyclin D positivity in tissue\r\nbiopsy; patients must have never received any prior therapy for their disease Newly diagnosed MCL: Patients should in general have bi-dimensional measurable disease with\r\ntheir biggest tumor less than cm; (bone marrow or gastrointestinal [GI] only involvement is acceptable) Newly diagnosed MCL: Ki protein (Ki) < % Newly diagnosed MCL: The patient has a prior or concurrent malignancy that in the opinion of the investigator, presents a greater risk to the patients health and survival, than of the MCL, within the subsequent months at the time of consent Newly diagnosed MCL: Prior treatment with ibrutinib Newly diagnosed MCL: Patients with blastoid and pleomorphic variants Newly diagnosed MCL: Ki- to be equal or more than % Newly diagnosed MCL: Central nervous system lymphoma Newly diagnosed MCL: Patients with bi-dimensional measurable disease with a tumor >= cm Patients with newly diagnosed brain metastases are eligible as long as they are not planned for WBRT upfront Cohort A: newly diagnosed AML, no prior cytotoxic chemotherapy Newly diagnosed patients with stage I and II follicular lymphoma, pathologically confirmed at MD Anderson Cancer Center (MDACC) to be grade or Untreated, non-transplant eligible, newly diagnosed mantle cell lymphoma with measurable disease as determined by computed tomography (CT), and bone marrow biopsy Elderly subjects (? years) with newly diagnosed AML must be treatment naive and unfit for intensive chemotherapy. Patients with ICGCTs who are newly diagnosed are excluded from the study Newly diagnosed disease Has a newly diagnosed tumor and a curative treatment option or approved therapy is available newly diagnosed untreated AML in patients ? years of age, if they are not candidates for standard available induction chemotherapy Subjects with (newly diagnosed or recurrent) metastatic cancer for whom surgery, radiation, or radiosurgery has not been advised by the treating physician. Newly diagnosed DIPG patients\r\n* Patients must have not received any prior therapy for treatment of their current CNS malignancy other than radiation therapy PART PATIENTS (NEWLY DIAGNOSED GBM) Patients should be newly diagnosed HNSCC, with no prior therapy for this disease Patients with newly diagnosed GCT newly diagnosed advanced breast cancer, then relapsed with documented evidence of progression while on or after only one line of endocrine therapy T.Bili. ? . x ULN (except in patients diagnosed with Gilbert's disease). Subjects ? years of age with newly diagnosed AML Diagnosis of newly diagnosed lymphoblastic lymphoma (patients must have < % tumor cells in bone marrow by morphology) newly diagnosed advanced/metastatic breast cancer, treatment nave Patients must either not be a candidate for docetaxel chemotherapy for newly diagnosed metastatic prostate cancer, as determined by their treating oncologist, or have declined this therapy Diagnosed with PNH Patients must be newly diagnosed with de novo acute myelogenous leukemia Patients must be newly diagnosed with histologically-proven hepatoblastoma Newly diagnosed stage IIIA/B NSCLC, PS - Patients must not have received any prior treatment for current or newly diagnosed breast cancer High-risk SMM per Mayo Clinic or Spanish PETHEMA (Treatment of Newly Diagnosed Patients with Acute Promyelocytic Leukemia) criteria Newly diagnosed, biopsy-proven stage -II breast cancer Is newly diagnosed with a curative treatment option available. INCLUSION CRITERIA FOR NEWLY DIAGNOSED PATIENTS WITH DIPG EXCLUSION CRITERIA FOR NEWLY DIAGNOSED PATIENTS WITH DIPG Newly diagnosed elderly AML patients (> years) unfit for intensive chemotherapy with cytarabine and anthracyclines are also eligible to this trial given that no clinically beneficial therapy exists for these patients Newly diagnosed or uncontrolled cancer-related central nervous system disease COHORT A: The subject must have newly diagnosed prostate cancer with a metastatic site(s) Subjects must be newly diagnosed or previously diagnosed with CNL or aCML; all patients must have a bone marrow biopsy completed during the screening or baseline period if one has not been done within days of day , cycle one Subjects who have been diagnosed with indolent NHL that has progressed. Patients with newly diagnosed, CD-positive mature T-cell lymphomas Patients with newly diagnosed PVNS with, at least, one measurable site of disease on MRI. Pre- and post-menopausal women newly diagnosed with DCIS histologically confirmed on breast core biopsy Newly diagnosed patients with no prior attempt at curative therapy Newly diagnosed, previously untreated patients with histologically or molecularly confirmed DSRCT Tumor: newly diagnosed non-disseminated diffuse intrinsic pontine glioma based on clinical AND radiographic finding Patients must have or fewer newly diagnosed metastatic lesions in the brain with a complete resection of at least one lesion as determined by the study neuroradiologist Newly diagnosed, treatment naive CP-CML (Cohort ) Newly diagnosed disease Patients who are newly diagnosed should have not received any other chemotherapeutic therapy (with the exception of dexamethasone) week before starting, or radiation therapy, weeks before starting Biopsy-proven KS involving skin, with or without visceral involvement, either newly diagnosed or refractory to or intolerant of one or more prior therapies Subjects must have newly diagnosed (within years), previously untreated prostate cancer without concurrent malignancy Newly diagnosed cGVHD defined by: Newly diagnosed inoperable cervical cancer treated with chemoradiation therapy with curative intent and life expectancy of at least months as assessed by the investigator o No CNS/spinal metastases Newly diagnosed patients with unilateral group D retinoblastoma Newly diagnosed, previously untreated patients with histologically or molecularly confirmed Ewing sarcoma Patients must have newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases Arm B: Patients with CML in AP or BP, either newly diagnosed or failing TKI therapy (i.e., Acute Group patients); Newly diagnosed patients who have not received prior therapy, with the exception of one short course of emergent chemotherapy in newly presenting patients with neurological compromise per provider decision Documented evidence of symptomatic MM, either newly diagnosed or relapsed/refractory Newly diagnosed de novo GBM with documented EGFRvIII expression in tumor tissue. Have newly diagnosed localized or locally advanced (TN-M or T-NanyM), potentially resectable disease without any prior systemic chemotherapy Patients with - newly diagnosed brain metastases The child must be a newly diagnosed patient with any type of malignant disease who will be or is receiving chemotherapy and/or radiation therapy Patient must be newly diagnosed or relapsed/progressed with a brain tumor that has not previously been treated with CRT\r\n* Note: COG therapeutic study participation is not required for ACCLP enrollment Diagnosed with ALL Individuals who have been diagnosed with lung cancer\r\n* Individuals are eligible regardless of date of diagnosis (newly diagnosed or long-term survivor), pathology type or stage of lung cancer, or history of other cancers Newly diagnosed prostate cancer (PCa) (within -months). The patient must not have received bevacizumab as an upfront treatment in newly diagnosed glioblastoma. Patients diagnosed with T-cell Lymphomas. Are newly diagnosed with prostate cancer Newly diagnosed solid tumor or lymphoma with histological verification A newly diagnosed, histologically proven cancer arising from the oral cavity and oropharynx Newly diagnosed, in need of a new line or therapy, or at a treatment decision making timepoint. PATIENTS: Newly diagnosed with any stage cancer Patients who are newly diagnosed with acute leukemia and hospitalized to receive their initial weeks of intensive induction chemotherapy for this disease Newly diagnosed with stage or higher cervical cancer within the past months Newly diagnosed with any stage of uterine cancer (both sarcoma and carcinosarcoma) in the past months Be diagnosed with cancer Newly diagnosed adult cancer patients from VICC and MMC or a participating caregiver designated by the patient Patient must be newly diagnosed (i.e., not relapsed) with any malignancy Patients with newly diagnosed or recurrent gynecologic cancer (ovarian, uterine, cervical, vaginal, vulvar) actively undergoing treatment (chemotherapy, surgery, or radiation therapy) at COH (including Duarte and South Pasadena campuses) newly diagnosed with I-III non-metastatic cancer Newly diagnosed with acute leukemia by pathology report Participants must be diagnosed with cancer Women who have been newly diagnosed with a first primary, epithelial ovarian cancer, have undergone surgical debulking and who will be treatment according to the Armstrong method Newly diagnosed, primary, epithelial ovarian cancer Newly diagnosed breast cancer patients Patient must be a newly diagnosed ALL, in first remission All patients with newly diagnosed lymphoma Newly diagnosed stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma with a > year life expectancy Men newly diagnosed with prostate cancer who are scheduled for prostatectomy (stage T or T) Newly diagnosed tumors: patients with newly diagnosed grade IV glioma who have had not been previously treated with cranial radiation therapy Newly diagnosed breast cancer patients Newly diagnosed primary brain tumor of any location and any histology (Cohort ) Patients must have histologically or cytologically proven advanced non-squamous NSCLC; patients may have newly diagnosed recurrent progressive or refractory disease which may be localized or wide spread Patients with histologically confirmed malignancy (local or metastatic, newly diagnosed or recurrent disease) Diagnosed with hypotonia An adult patient with a newly diagnosed, untreated primary lung cancer diameter mm or more; AND Have one of the following disease histories: \r\n* Newly-diagnosed or recurrent (local, regional, metastatic) malignant melanoma or breast cancer patients in whom SLN mapping is indicated \r\n** Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas \r\n** Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region\r\n** Newly-diagnosed patients with previous excisional biopsy OR \r\n** Newly-diagnosed gynecologic cancer patients in whom SLN mapping and surgical excision is indicated Newly diagnosed, untreated mass in posterior fossa, either benign or malignant Newly-diagnosed or recurrent (local, regional, metastatic) metastatic melanoma or malignant brain tumor patients with:\r\n* Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas, or malignant brain tumor\r\n* Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region\r\n* Newly diagnosed patients with previous excisional biopsy Newly diagnosed with esophageal cancer. Patient is diagnosed with cancer Be diagnosed with T or greater LABC, any N and M. Patients with newly diagnosed and untreated stage II and II breast cancer scheduled to undergo neoadjuvant chemotherapy Patients who will be undergoing surgery for newly-diagnosed glioblastoma Women must have newly diagnosed histologically or cytologically confirmed endometrial cancer Have newly diagnosed infiltrating ductal carcinoma of the breast All cancer types and both newly diagnosed and previously treated patients will be included Newly diagnosed with clinically node-negative breast cancer or melanoma being staged with SLN biopsy Patients with newly diagnosed, relapsed, or refractory EBV-associated or KSHV-associated malignancies including human immunodeficiency virus (HIV)-associated lymphomas are potentially eligible Hospitalized for newly diagnosed acute leukemia Be diagnosed with a neurodegenerative disease Providing surgical treatment for newly diagnosed breast cancer patients PHASE II: Women newly diagnosed with breast cancer on the day they meet with their surgeon for their initial consultation after the visit Newly diagnosed breast cancer Newly diagnosed suspected or proven clinical stage I NSCLC (T or T, N, M) with no prior treatment for this disease Histologically confirmed newly diagnosed G MG Patients must have suspected refractory or relapsed pre-B cell ALL or mixed phenotype acute leukemia (MPAL), or if newly diagnosed, the patient must be years of age or older Newly diagnosed, de novo or secondary, previously untreated AML Participants must have progressive, advanced cancer as defined by one of the following:\r\n* Newly diagnosed, untreated advanced disease\r\n* Newly diagnosed, untreated metastatic recurrence of earlier stage disease (previous treatment of early stage disease allowed)\r\n* Clinical determination of progressive disease on previous systemic therapy as evidenced by plan to change treatment; any number of prior therapies are acceptable excluding previous EGFR kinase inhibitors